JAK2 Inhibitor V

Research use only, not for human use.

NSC 42834(JAK2 Inhibitor V, Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.

NSC 42834, also known as JAK2 Inhibitor V, is an inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK2, displaying IC50 values between 10 and 30 μM.

NSC 42834 (JAK2 Inhibitor V) selectively inhibited Jak2 kinase function with no effect on Tyk2 or c-Src kinase function. NSC 42834 significantly inhibited proliferation of the Jak2-V617F-expressing, human erythroleukemia cell line, HEL 92.1.7. The NSC 42834-mediated reduction in cell proliferation correlated with reduced Jak2 and STAT3 tyrosine phosphorylation levels as well as marked cell cycle arrest. Finally, NSC 42834 inhibited the growth of hematopoietic progenitor cells isolated from the bone marrow of an essential thrombocythemia patient harboring the Jak2-V617F mutation and a polycythemia vera patient carrying a Jak2-F537I mutation.

——

NSC 42834 | Janus-Associated Kinase Inhibitor V

Others

Other Targets

JAK2| JAK2 (V617F)

Cancer

——

195371-52-9

344.45

C23H24N2O

>98% (HPLC)

DMSO : ≥ 43 mg/mL; 124.84 mM

O=C(C(CCc1ccccn1)(CCc1ccccn1)C)c1ccccc1

2-methyl-1-phenyl-4-(pyridin-2-yl)-2-(2-(pyridin-2-yl)ethyl)butan-1-one

(-20℃)

With Ice Pack

≥ 2 years